Accessibility Menu
MannKind logo

MannKind(NASDAQ) MNKD

Market Cap$1.24BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-94%
5 Year-4%
1 Year+12%
1 Month-8%
$3.89
-5.12%
-0.21Today
After hours$3.89-$0.01 (-0.13%)
MannKind last closing stock price
MetricPriceDate
Last closeUSD 3.892026-08-06
MannKind stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.35%USD 4.112026-07-30
1 month-7.82%USD 4.222026-07-07
3 month+10.51%USD 3.522026-05-08
Year to date-31.39%USD 5.672025-12-31
1 year+12.27%USD 3.472025-08-06
3 year-15.43%USD 4.602023-08-07
5 year-3.71%USD 4.042021-08-06
Since inception-94.18%USD 70.402004-07-28

MannKind Financials at a Glance

Market Cap

$1.24BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$393.63M

Net Income (TTM)

-$43.61M

EPS (TTM)

-$0.08

P/E Ratio

-49.87

Dividend

$0.00

Beta (Volatility)

1.11 (Average)

Price

$3.89

Volume

9,306,198.103

Open

$3.82

Previous Close

$3.89

Daily Range

$3.69 - $3.93

52-Week Range

$2.23 - $6.51

Estimated Earnings Date

Nov 4, 2026

MNKD: Motley Fool Moneyball Superscore

66

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MannKind

MannKind makes medicines that patients breathe in instead of inject. These products help people manage diabetes and lung diseases easily. The company also builds wearable devices to deliver treatments.

Medicine You Can Breathe

  • Afrezza: Inhaled human insulin powder that helps adults with diabetes manage their blood sugar.
  • Tyvaso DPI: Breath-powered treatment for lung-related blood pressure issues, commercialized by a partner.
  • Furoscix: Wearable device and medicine combination used to treat fluid buildup in heart failure patients.
  • V-Go: Mechanical insulin delivery patch that provides steady and mealtime doses without multiple injections.

Making Big Moves

  • Acquired scPharma in October 2025 to expand into treatments for heart failure.
  • Expanded a drug development agreement with United Therapeutics in August 2025.
  • Purchased the V-Go product line from Zealand in May 2022.
  • Partnered with Cipla to launch inhaled insulin in India in December 2025.

Why Their Tech Matters

MannKind uses its Technosphere platform to turn liquid medicines into powders for deep lung delivery. It operates a dedicated manufacturing facility in Connecticut to produce these complex drug-device products.

The Latest Numbers

  • Revenue reached $112 million in Q4 2025, up 45.8% from Q4 2024.
  • Gross profit was $87.8 million in Q4 2025, up 53.6% year-over-year.
  • Operating income worsened to -$7.7 million in Q4 2025 from $26.5 million.
  • Net income fell to -$15.9 million in Q4 2025, worsening from $7.4 million in Q4 2024.

Bottom Line

MannKind has evolved from a single-product company into a diversified developer of inhaled therapies. Its focus on specialized drug delivery and strategic acquisitions supports its expansion in the biopharmaceutical market.

AI Generated • May 3, 2026

Industry

Biotechnology

Employees

592

CEO

Michael E. Castagna, MBA

Headquarters

Danbury, CA 06810, US

MNKD Financials

Key Financial Metrics (TTM)

Gross Margin

75.69%

Operating Margin

1.97%

Net Income Margin

-11.08%

Return on Equity

78.60%

Return on Capital

9.19%

Return on Assets

-5.96%

Earnings Yield

-2.01%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.24BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

319.39M

Volume

9.31M

Avg. Volume

5.51M

Financials (TTM)

Gross Profit

$297.93M

Operating Income

$7.75M

EBITDA

$30.74M

Operating Cash Flow

-$13.85M

Capital Expenditure

-$11.96M

Free Cash Flow

-$25.81M

Cash & ST Invst.

$111.13M

Total Debt

$330.85M

MannKind Performance Analysis

MannKind annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 99,770,00032.2%
20232023-12-31USD 198,962,00099.4%
20242024-12-31USD 285,504,00043.5%
20252025-12-31USD 348,966,00022.2%
MannKind sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.3%
Q42025-12-3136.3%
Q12026-03-31-19.5%
Q22026-06-3021.3%
MannKind annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.344.7%
20232023-12-31USD -0.04-86.9%
20242024-12-31USD 0.10N/A
20252025-12-31USD 0.02-80.8%
MannKind sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-301119.0%
Q42025-12-31-291.4%
Q12026-03-31-10.0%
Q22026-06-30-11.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$109.37M

+42.9%

Gross Profit

$79.83M

+42.7%

Gross Margin

72.99%

N/A

Market Cap

$1.24BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.10M

N/A

Employees

592

N/A

Net Income

-$19.03M

-2949.1%

EBITDA

$12.94M

+32.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$111.13M

-37.9%

Total Debt

$330.85M

+606.6%

Accounts Receivable

$43.21M

+59.2%

Inventory

$44.42M

+55.9%

Long Term Debt

$328.77M

+2985.3%

Short Term Debt

$2.08M

-94.3%

Return on Assets

-5.96%

N/A

Return on Invested Capital

1.32%

N/A

Free Cash Flow

-$30.70M

-491.9%

Operating Cash Flow

-$23.74M

-365.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
JANXJanux Therapeutics, Inc.
$16.10+0.63%
IMCRImmunocore Holdings plc
$34.50+3.63%
ABCLAbCellera Biologics Inc.
$6.53+10.30%
AUPHAurinia Pharmaceuticals Inc.
$16.13+6.19%

Trending Stocks

Symbol / CompanyPricePrice Chg
TTDThe Trade Desk
$17.67-0.07%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$26.93-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$72.03-0.01%
SPCXSpace Exploration Technologies
$114.92+0.06%

Questions About MNKD

What is the current price of MannKind?

MannKind is trading at $3.89 per share.

What is the 52-week range for MannKind?

Over the past 52 weeks, MannKind has traded between $2.23 and $6.51.

How much debt does MannKind have?

As of the most recent reporting period, MannKind reported total debt of $436.67M.

How much cash does MannKind have on hand?

MannKind reported $52.83M in cash and cash equivalents in its most recent financial results.

What is MannKind’s dividend yield?

MannKind does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.